Stephens analyst Raj Kumar raised the firm’s price target on HCA Healthcare (HCA) to $500 from $450 and keeps an Overweight rating on the shares. Q3 revenue maintained support from Medicaid supplemental payments, notes the analyst, who notes that HCA remains committed to delivering its long-term 2% to 3% volume target when framing 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $482 from $449 at RBC Capital
- HCA Healthcare: Hold Rating Amid Policy Uncertainties and Volume Growth Concerns
- HCA Healthcare price target raised to $470 from $430 at BofA
- HCA Healthcare price target raised to $490 from $380 at TD Cowen
- HCA Healthcare price target raised to $494 from $445 at Barclays